Abstract: A packaging body 141 for containing a thin tablet 100, including an accommodation member 142, wherein the accommodation member 142 includes an inlet 147 and an accommodation portion 146 recessed from the inlet 147, and the accommodation member 142 has a structure in which at least a portion of the thin tablet 100 accommodated in the accommodation portion 146 moves toward the inlet 147 upon application of a force, by an object inserted from the inlet 147, to a portion of the thin tablet 100 accommodated in the accommodation portion 146.

Abstract: Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.

Abstract: An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.

Abstract: Disclosed is a method for producing a porous orodispersible film, having the following steps: i) forming a suspension of a pharmaceutically acceptable solvent, a pharmaceutically acceptable matrix material, and a pharmaceutically acceptable binder, said solvent being selected such that the pharmaceutically acceptable matrix material substantially does not dissolve in it, whereas the pharmaceutically acceptable binder is dissolved in the solvent, ii) casting the suspension onto a neutral support, thereby forming a wet film, and iii) drying the wet film and obtaining a dry film. The films produced in this manner have a closed surface on the lower face whereas the upper face is porous, thereby allowing the application of a pharmaceutically active ingredient in the form of a suspension or a solution for example.

Abstract: A catheter shield is described herein. The catheter shield has a sleeve configured to receive and house a proximal end of a catheter projecting from a patient, a retention structure configured as an outer protective barrier, a first adhesive layer disposed on a bottom portion of the retention structure, wherein the first adhesive layer provides adherence to the patients skin; a second adhesive layer provided on an outer edge of the sleeve and located within a diameter of the retention structure, wherein the second adhesive layer is configured as a middle protective barrier, a third adhesive layer located within a diameter of the second adhesive, wherein the third adhesive is layer is configured as an inner protective barrier, and wherein the third adhesive layer comprises a moisture indicator posited thereon.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: Methods and utensils are provided for administering plant extract(s) at controlled amount via smoking, as well as for providing complexes of honey and plant extracts. Plant extract(s) may be used in utensils that are inserted into a smoking appliance, and have indications of the compounds and/or characteristics of the plant extract. Upon smoking the smoking appliance, the plant extracts may be inhaled in pre-defined amounts. Using plant extracts in such way enables standardization of amounts and components thereof, and may be particularly applicable to cannabis oils. Furthermore, complexes of honey and plant extracts may be provided by letting bees step on or be soiled by plant extracts on their way into the beehive, causing them to incorporate the plant extracts into the honey preparation process. Resulting complexes may be a preferable and particularly beneficial way of administering plant extracts, e.g., cannabis extracts.

Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.

Abstract: The most prevalent pharmaceutical dosage forms at present, the oral-delivery tablets, are granular solids. An inherent limitation of such granular solids for drug release applications is the unpredictability of the microstructure. As a result, the drug release rate and other properties are difficult to control, and their range is also limited. Presented herein, therefore, is a solid dosage form with predictable microstructure and properties. The dosage form includes a drug-containing solid comprising a three dimensional structural framework of one or more two-dimensional structural elements or sheets.

Abstract: A dental medicament applicator is disclosed. In one embodiment, a retention device is sized for insertion at a dental site, such as an interproximal site. The retention device includes a body and at least one matrix within the body containing a topical substance, such as a fluoride-containing chemical agent, silver diamine fluoride, or a peptide-based chemical agent, for example. One or two wings may be selectively separably coupled to respective ends of the body. The body, in response to being physically affixed to the dental site, delivers the topical substance at a controlled rate to the dental site.

Abstract: A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing a matrix composition including a combination of nicotine and a water-soluble composition.

Abstract: The present invention relates to a kit and a probe for detecting porous dental hydroxyapatite that includes a protein capable of binding porous dental hydroxyapatite or a detector thereof. The invention also relates to a method for detecting a condition involving porous dental hydroxyapatite that includes detecting in or on a tooth or a sample of the tooth of a subject a protein bound to porous dental hydroxyapatite. The invention also relates to methods for detecting a hypomineralisation developmental dental defect or detecting intact and/or broken MIH enamel, and to a kit and method for removing a protein bound to porous dental hydroxyapatite.

Abstract: The present invention resides in a method for producing jellyfish collagen hydrogels and kits for producing the same. The jellyfish collagen hydrogels can be used in the culture of cells. According to the invention, there is a process for producing jellyfish collagen hydrogels comprising jellyfish collagen fibrils, said process comprising the steps of: mixing a solution of purified jellyfish collagen and an aqueous neutralisation buffer; and incubating the mixture for a sufficient time to enable jellyfish collagen fibrils to form, wherein a cross-linking agent is either added during to mixing step or during or after the incubation of the mixture.

Abstract: An object of the invention is to provide a mucoadhesive oral preparation having high drug absorption rate and rapid drug release rate. The means for solving the problem is a mucoadhesive oral preparation having (a) a basal layer substantially consisting of a water-insoluble material, (b) a drug layer locating above the basal layer and containing a drug but not containing mucoadhesive material, and (c) an adhesive portion locating on a portion of the surface of the drug layer side of the oral formulation and containing mucoadhesive material.

Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

Abstract: Improved skin-adhesive compositions for bonding a substrate, such as an absorbent article, to skin are disclosed. More particularly, the skin-adhesive composition has an improved, yet gentle, adhesion to the skin of a user, while maintaining strong, effective bonding to various inanimate, non-skin substrates. In one embodiment, the skin-adhesive composition can provide one or more skin benefit agents to the user. The skin-adhesive composition may applied to an absorbent article, such as a panty-liner, sanitary napkin, or an incontinence article, for directly adhering the article to the skin of a user.

Abstract: Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.

Abstract: A method of improving the condition of teeth in a human mouth by continuing events of applying a composition containing calcium and a source of OH? ions, optionally in combination with amino acid/protein containing casein, so that the composition mixes with saliva and forms a slurry, followed by swishing the result around in the human mouth; the method also including, between at least two continuing events, applying a more solid composition that contains calcium and OH? and optionally casein, to problem areas of the teeth, such as where they are worn or chipped, and maintaining the contact by not intentionally removing it.

Abstract: The invention relates to an injection device which includes a handle and a guard which together enclose a movable cartridge which can contain liquid material to be injected, and further enclose a movable injector that includes a needle, the needle being attached to a housing where the housing is attached to the cartridge, the device also including a delivery mechanism whereby the needle is moved from a retracted to an extended position, and independently the volume of the chamber may be adjusted to expel the contents thereof through the needle and into a subject in need thereof. The injection device may be communicatively connected to a control unit so as to provide a dermal injection system.

Abstract: Various formulations (to be used in the form of a single-segment or multi-segment transdermal patch) of bioactive compounds for pain management are described/disclosed. The multi-segmented transdermal patch can include one or more compatible bioactive compounds in each segment. Furthermore, formulations may include silk fibroin and/or microemulsion/nanoemulsion of bioactive compounds and/or microencapsulation/nanoencapsulation of bioactive compounds.

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Abstract: Adjuvants for agrochemical active formulation and methods of providing adjuvancy in agrochemical formulations are disclosed. An agrochemical formulation may comprise a first adjuvant comprising a fatty ester of a C3 to C8 polyol, or an oligomer thereof having from 2 to 5 repeat units, a co-adjuvant comprising an alkoxylated fatty alcohol having a C4 to C30 fatty chain and from 1 to 30 oxyalkylene groups, and at least one agrochemical active. Use of a combination of a first adjuvant comprising a fatty ester of a C3 to C8 polyol, or an oligomer thereof having from 2 to 5 repeat units, and a co-adjuvant comprising an alkoxylated fatty alcohol having a C4 to C30 fatty chain and from 1 to 30 oxyalkylene groups and a method for treating vegetation to control pests is also disclosed.

Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Abstract: The object is to provide a wrinkle improving agent having an excellent wrinkle improving effect. A compound expressed by the following Formula (1), or an acid addition salt thereof is used as an active ingredient of a wrinkle improving agent. (Wherein X represents an alkylene group having 1 to 2 carbon atoms in which a hydrogen atom may be substituted with a methyl group, Y represents COOR1 or CH2OR2, R1 represents a hydrogen atom, or an optionally branched alkyl group having 1 to 6 carbon atoms, and R2 represents a hydrogen atom, or an optionally branched acyl group having 1 to 6 carbon atoms.

Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.

Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Abstract: Methods of reducing gingivitis and plaque buildup by administering an oral care product (a dentifrice or a mouthwash) that consists essentially of a sea salt, preferably Dead Sea salt, and xylitol. In mouthwash and dentifrice embodiments, the oral care product contains aloe vera leaf juice.

Abstract: The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.

Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.

Abstract: An oral tobacco product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix and tobacco fibers embedded in the mouth-stable polymer matrix. The oral tobacco product can be formed by extruding a mixture of mouth-stable polymer and tobacco fibers.

Abstract: Described herein are aqueous compositions comprising polymers, which deliver a polymer film to surfaces of the oral cavity to relieve dry mouth; and methods of preparing and using the same.

Abstract: A dust-reduced nicotine-containing granulate comprising a homogenous mixture of nicotine or a pharmaceutically acceptable nicotine derivative and an excipient, the granulate having a particle size of at least 150 ?m. Method for the preparation of a dust-reduced nicotine-containing granulate, and use of the nicotine-containing granulate for the preparation of pharmaceutical products.

Abstract: A method of smoothing teeth by, for instance, filling in cracks, chips and eroded areas by applying calcium and/or casein and/or phosphate and a source of OH? ions thereto. The method optionally provides that very thin layer(s) of dental cement be interlaced with other applied materials, and that the results be maintained in contact with the teeth involved by application of a composition of matter that adheres to said teeth and holds the results in place, while allowing at least some permeation of saliva therethrough. The method can optionally involve application of a backing strip or tray or the like to secure the other materials in place, but this is not a requirement where the composition of matter is sufficiently securing.

Abstract: The present disclosure relates to emulsions for parenteral administration comprising 1000 to 5000, preferably 1500 to 3000 IU, vitamin A per ml, wherein the emulsions are free of polysorbates and polyoxyethylene/polyoxypropylene block copolymers. The present disclosure further relates to a method for manufacturing the compositions of the disclosure as well as to the use of the compositions of the disclosure.

Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.

Abstract: The present disclosure relates generally to oral compositions and methods for inhibiting the formation of plaque biofilm by salivary bacteria, and more particularly, to oral compositions comprising a combination of magnolia bark extract (MBE) and L-arginine, N?-lauroyl ethyl ester (LAE). The oral compositions are useful for improving oral health, including inhibiting the formation of plaque biofilm by salivary bacteria and reducing plaque adherence to teeth.

Abstract: The disclosure provides a composition for inhibiting thrombosis. The composition includes 5 to 25% by weight of Fish Oil, 15 to 55% by weight of Willow Bark Extract, and 0.2 to 5% by weight of Vitamin E.

Abstract: Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavoring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains.

Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response.

Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.

Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, exhausted tobacco fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.

Abstract: Described herein are compositions comprising capsaicin and methods of treating muscle cramping in a subject, comprising orally administering to the subject a composition comprising capsaicin and an excipient.

Abstract: An orthodontic correction device set up within an oral cavity of a patient. It includes a bone screw member that has a plate, the plate includes at least a positioning portion, and a surface of the plate includes at least a fixing member; at least a bone screw is in connection with at least a positioning portion of the bone screw member, and that is fixed by implanting into the oral cavity; at least a base body is assembled on a surface of the teeth and including a connecting portion; and at least an elastic member, a fixing end of the elastic member is assembled and fixed on the fixing member of the bone screw member, a functioning end of the elastic member is in mutual connection with the connecting portion of the base body, and an orthodontic correction force is formed between the fixing end and the functioning end.

Abstract: The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid.

Abstract: An oral tobacco product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix and tobacco fibers embedded in the mouth-stable polymer matrix. The oral tobacco product can be formed by extruding a mixture of mouth-stable polymer and tobacco fibers.

Abstract: Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.

Abstract: A pharmaceutical composition which is Rapidly Dissolved in a mouth, comprising (a) agglomerate units which is consisted of a discontinuous phase comprising the first component; and a continuous phase comprising the second component; and (b) a pharmaceutically acceptable excipient, in which the pharmaceutical composition is characterized in that the first component is an effective ingredient exhibiting the pharmacological activity, and the second component is sugar or sugar alcohol is provided.

Abstract: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.

Abstract: The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.